Dextromethorphan/Bupropion: A Novel Oral NMDA (N-methyl-d-aspartate) Receptor Antagonist with Multimodal Activity
Open accessAbstract
Although currently available antidepressants increase monoamine levels soon after the start of treatment, therapeutic benefits are often delayed by several weeks and the majority of patients with major depressive disorder fail to achieve an adequate response to first- or second-line therapies targeting monoamines. The recent approval of the NMDA (N-methyl-d-aspartate) antagonist esketamine given intranasally for treatment-resistant depression has reinforced the need for agents with rapid onset with alternate mechanisms of action. Dextromethorphan/bupropion, an investigational medicine currently in development, is one such candidate.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Dextromethorphan-bupropion has demonstrated efficacy after only one week of treatment.
“while dextromethorphan-bupropion has demonstrated efficacy after only one week of treatment [19]”
From Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder (2023) · cites this paper as [19]
The section on major depressive disorder and treatment-resistant depression reports improved depression scores and higher remission rates with dextromethorphan/bupropion by week 2 compared with bupropion alone. It supports relatively rapid efficacy, but does not establish efficacy after only one week. Page information was not available in our copy. (LLM, conf=0.85)
Experimental — accuracy not yet measuredDXM-bupropion operates through a broader multimodal profile: weak NMDA antagonism is complemented by sigma 1 receptor activation and dopamine transporter inhibition.
“Weak NMDA antagonism is complemented by sigma 1 receptor activation and dopamine transporter inhibition, shaping excitability, stress resilience, and neurotrophic tone alongside glutamatergic mechanisms [57,58,59].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [59]
The Summary and Conclusions (Figure 3; page not provided) identifies dextromethorphan as an NMDA antagonist and sigma-1 agonist, and bupropion as a dopamine transporter inhibitor, supporting the multimodal profile. The paper does not characterize the NMDA antagonism as weak. Its discussion of neural plasticity does not establish the citing sentence’s further claim about stress resilience and neurotrophic tone for these combined mechanisms. (LLM, conf=0.84)
Experimental — accuracy not yet measuredAuvelity is hypothesized to work via NMDAR antagonism of dextromethorphan, which is prolonged by bupropion, a norepinephrine-dopamine reuptake inhibitor.
“Auvelity is hypothesized to work via the NMDAR antagonism of dextromethorphan, which is prolonged by bupropion, a norepinephrine-dopamine reuptake inhibitor [187]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [187]
Bupropion increases the bioavailability of dextromethorphan by CYP2D6 inhibition.
“Bupropion, a dopamine and norepinephrine reuptake inhibitor, competitively inhibits CYP2D6, which extends dextromethorphan’s half-life to 22 hours [16,17,19].”
From Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder (2023) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · see citing works
Sen, S., Duman, R., & Sanacora, G. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.005 · Cited by 1,232 · see citing works
(2008) · Cited by 889 · see citing works
Self-citationAttenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism
Williams, N. R., Heifets, B. D., Blasey, C., Sudheimer, K., Pannu, J., Pankow, H., Hawkins, J., Birnbaum, J., Lyons, D. M., Rodriguez, C. I., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18020138 · Cited by 519 · see citing works
Stahl′s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications
Andrade, C. (2010) · Mens Sana monographs · doi:10.4103/0973-1229.58825 · Cited by 509 · see citing works
Nierenberg, A. A., Husain, M. M., Trivedi, M. H., Fava, M., Warden, D., Wisniewski, S. R., Miyahara, S., & Rush, A. J. (2010) · Psychological Medicine · doi:10.1017/s0033291709006011 · Cited by 458 · see citing works
Blier, P., Ward, H. E., Tremblay, P., Laberge, L., Hébert, C., & Bergeron, R. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09020186 · Cited by 316 · see citing works
McClintock, S. M., Husain, M. M., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Trivedi, M. H., Cook, I., Morris, D., Warden, D., & Rush, A. J. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31820ebd2c · Cited by 234 · see citing works
Glutamatergic Modulators: The Future of Treating Mood Disorders?
Zarate, C., Machado-Vieira, R., Henter, I., Ibrahim, L., Diazgranados, N., & Salvadore, G. (2010) · Harvard Review of Psychiatry · doi:10.3109/10673229.2010.511059 · Cited by 228 · see citing works
Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder
Niciu, M. J., Ionescu, D. F., Richards, E. M., & Zarate, C. A. (2013) · Journal of Neural Transmission · doi:10.1007/s00702-013-1130-x · Cited by 157 · see citing works
Werling, L. L., Keller, A. B., Frank, J. G., & Nuwayhid, S. J. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.06.013 · Cited by 102 · see citing works
Deyama, S., Bang, E., Wohleb, E. S., Li, X., KATO, T., Gerhard, D. M., Dutheil, S., Dwyer, J. M., Taylor, S. R., Picciotto, M. R., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17121368 · Cited by 99 · see citing works
Robson, M. J., Elliott, M., Seminerio, M. J., & Matsumoto, R. R. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.08.002 · Cited by 94 · see citing works
Freudenberg, F., Celikel, T., & Reif, A. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.03.005 · Cited by 92 · see citing works
Lauterbach, E. C. (2012) · Medical Hypotheses · doi:10.1016/j.mehy.2012.02.012 · Cited by 52 · see citing works
Involvement of AMPA receptors in the antidepressant-like effects of dextromethorphan in mice
Nguyen, L., & Matsumoto, R. R. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.03.024 · Cited by 51 · see citing works
New Therapeutic Strategy for Mood Disorders
Crupi, R., Marino, A., & Cuzzocrea, S. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711797200417 · Cited by 20 · see citing works
Kachur, J. F., Morgan, D. W., & Gaginella, T. S. (1986) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)23365-1 · Cited by 15 · see citing works
Effect of dextromethorphan and levomethorphan on gastric emptying and intestinal transit in the rat.
Gaginella, T. S., Bertko, R. J., & Kachur, J. F. (1987) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22604-0 · Cited by 15 · see citing works
Explaining Naltrexone’s Interference With Ketamine’s Antidepressant Effect
Wang, M., & Kaplin, A. I. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19010044 · Cited by 11 · see citing works
Berman, F. W., & Murray, T. F. (1996) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/(sici)1522-7146(1996)11:5 · Cited by 2 · see citing works
Heifets, B. D., Williams, N., Blasey, C. M., Sudheimer, K. D., Rodríguez, C. I., & Schatzberg, A. F. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19010044r · Cited by 1 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Cholinergic System and Its Therapeutic Importance in Inflammation and Autoimmunity
Halder, N., & Lal, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.660342 · Cited by 186 · see citing works
Ketamine in neuropsychiatric disorders: an update
Johnston, J. N., Kadriu, B., Kraus, C., Henter, I. D., & Zarate, C. A. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01632-1 · Cited by 108 · see citing works
Glutamatergic Modulators for Major Depression from Theory to Clinical Use
McIntyre, R. S., & Jain, R. (2024) · CNS Drugs · doi:10.1007/s40263-024-01114-y · Cited by 69 · see citing works
Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder
McCarthy, B., Bunn, H., Santalucia, M., Wilmouth, C., Muzyk, A., & Smith, C. M. (2023) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.23.1081 · Cited by 63 · see citing works
“In addition to NMDA antagonism, dextromethorphan is a sigma-1 agonist and inhibits serotonin and norepinephrine reuptake [19].”
BackgroundLv, S., Yao, K., Zhang, Y., & Zhu, S. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109378 · Cited by 57 · see citing works
Marine Natural Products, Multitarget Therapy and Repurposed Agents in Alzheimer’s Disease
Martins, M., Silva, R., Pinto, M. M. M., & Sousa, E. (2020) · Pharmaceuticals · doi:10.3390/ph13090242 · Cited by 53 · see citing works
Majeed, A., Xiong, J., Teopiz, K., Ng, J., Ho, R., Rosenblat, J., Phan, L., Cao, B., & McIntyre, R. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.1898588 · Cited by 50 · see citing works
Analgesic Alkaloids Derived From Traditional Chinese Medicine in Pain Management
Jiang, W., Tang, M., Yang, L., Xu, Z., Gao, J., Jiao, Y., Li, T., Tie, C., Gao, T., Han, Y., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.851508 · Cited by 46 · see citing works
Dextromethorphan/Bupropion: First Approval
Keam, S. J. (2022) · CNS Drugs · doi:10.1007/s40263-022-00968-4 · Cited by 46 · see citing works
Clinical specificity profile for novel rapid acting antidepressant drugs
Scala, M., Fanelli, G., De Ronchi, D., Serretti, A., & Fabbri, C. (2023) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000488 · Cited by 41 · see citing works
Akbar, D., Rhee, T. G., Ceban, F., Ho, R., Teopiz, K. M., Cao, B., Subramaniapillai, M., Kwan, A. T. H., Rosenblat, J. D., & McIntyre, R. S. (2023) · CNS Drugs · doi:10.1007/s40263-023-01032-5 · Cited by 38 · see citing works
The Relationship Between 5-Hydroxytryptamine and Its Metabolite Changes With Post-stroke Depression
Gu, S., He, Z., Xu, Q., Dong, J., Xiao, T., Liang, F., Ma, X., Wang, F., & Huang, J. H. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.871754 · Cited by 31 · see citing works
Chaki, S., & Watanabe, M. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109348 · Cited by 28 · see citing works
Montano, C. B., Jackson, W., Vanacore, D., & Weisler, R. H. (2023) · Postgraduate Medicine · doi:10.1080/00325481.2023.2189868 · Cited by 24 · see citing works
Cooper, T., Seigler, M. D., & Stahl, S. M. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231158891 · Cited by 21 · see citing works
Self-citationRapid-acting oral drug (Auvelity) for major depressive disorder
Khabir, Y., Hashmi, M. R., & Asghar, A. A. (2022) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2022.104629 · Cited by 17 · see citing works
Clinical pharmacological innovation in the treatment of depression
Witkin, J. M., Golani, L. K., & Smith, J. L. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2198703 · Cited by 16 · see citing works
Sackeïm, H. A., Aaronson, S. T., Bunker, M. T., Conway, C. R., George, M. S., McAllister-Williams, H., Prudic, J., Thase, M. E., Young, A. H., & Rush, A. J. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.05.046 · Cited by 13 · see citing works
Benefits and risks of esketamine nasal spray continuation in treatment-resistant depression
Price, M. Z., & Price, R. L. (2024) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2024.100104 · Cited by 13 · see citing works
Back to the Future: Esmethadone, the (Maybe) Nonopiate Opiate, and Depression
Nemeroff, C. B. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2021.21121204 · Cited by 11 · see citing works
McIntyre, R. S., Rodrigues, N. B., Lipsitz, O., Lee, Y. L., Cha, D. S., Gill, H., Lui, L. M. W., Subramaniapillai, M., Kratiuk, K., Ho, R., et al. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.03.053 · Cited by 11 · see citing works
Pedraz‐Petrozzi, B., Deuschle, M., & Gilles, M. (2023) · Clinical Case Reports · doi:10.1002/ccr3.7045 · Cited by 10 · see citing works
Dextromethorphan/Bupropion: A Novel Treatment for Patients With Major Depressive Disorder
Willett, K. C., Bond, L. R., Morrill, A. M., Dima, L., & Ifteni, P. I. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001699 · Cited by 10 · see citing works
Emerging therapies for treatment of agitation, psychosis, or apathy in Alzheimer’s disease
Wang, H. J., Chinna‐Meyyappan, A., Feldman, O. J., & Lanctôt, K. L. (2024) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2024.2363215 · Cited by 9 · see citing works
Lin, C.-H., Tao, P., Tsay, H.-J., Chiang, Y., Chang, W.-T., Ho, I. K., & Shie, F. (2021) · Behavioural Neurology · doi:10.1155/2021/6301458 · Cited by 9 · see citing works
Antipsychotic Drugs Efficacy in Dextromethorphan-Induced Psychosis
Zaremba, M., Serafin, P., & Kleczkowska, P. (2023) · Biomedicines · doi:10.3390/biomedicines11010123 · Cited by 9 · see citing works
Naguy, A., & Badr, B. (2021) · CNS Spectrums · doi:10.1017/s1092852921000365 · Cited by 8 · see citing works
Combinations of dextromethorphan for the treatment of mood disorders - a review of the evidence
Parincu, Z., & Iosifescu, D. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2192402 · Cited by 8 · see citing works
Multi-Target-Directed Ligand Approach in Anti-Alzheimer’s Drug Discovery
Patil, V. M., Masand, N., Gautam, V., Kaushik, S., & Wu, D. H. (2023) · Springer eBooks · doi:10.1007/978-981-99-2657-2_13 · Cited by 9 · see citing works
A Critical View on New and Future Antidepressants
Serretti, A. (2024) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.23.1145 · Cited by 9 · see citing works
Recent Developments in Pharmacotherapy of Depression: Bench to Bedside
Shad, M. U. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13050773 · Cited by 8 · see citing works
Stahl, S. M. (2019) · CNS Spectrums · doi:10.1017/s109285291900155x · Cited by 8 · see citing works
Self-citationA Comprehensive Review of Novel FDA-Approved Psychiatric Medications (2018-2022)
Giliberto, S., Shishodia, R., Nastruz, M., Brar, C., Bulathsinhala, S., Terry, J., Pemminati, S., & Shenoy, S. K. (2024) · Cureus · doi:10.7759/cureus.56561 · Cited by 7 · see citing works
Current drug targets for the treatment of depression
Pathak, G., Nigade, A., Anitha, K., & Bhatt, S. (2025) · Brain Disorders · doi:10.1016/j.dscb.2025.100270 · Cited by 7 · see citing works
Patil, A. S., & Koul, S. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128309913240704095334 · Cited by 6 · see citing works
Selective α3β4 Nicotinic Acetylcholine Receptor Ligand as a Potential Tracer for Drug Addiction
Kanasuwan, A., Deuther‐Conrad, W., Chongruchiroj, S., Sarasamkan, J., Chotipanich, C., Vajragupta, O., & Arunrungvichian, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043614 · Cited by 6 · see citing works
Dextromethorphan: From Cough Suppressant to Antidepressant
Kverno, K. S. (2022) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20221005-02 · Cited by 6 · see citing works
Maji, S., Mishra, A., Mohapatra, D., Mishra, B. R., Jena, M., Srinivasan, A., & Maiti, R. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.116257 · Cited by 5 · see citing works
Dextromethorphan/bupropion in major depressive disorder: a profile of its use
Blair, H. A. (2023) · Drugs & Therapy Perspectives · doi:10.1007/s40267-023-01009-w · Cited by 5 · see citing works
Blanco, J., Quimbaya, P., Mena, M., Dodd, S., & Bustos, R. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2374024 · Cited by 5 · see citing works
Gupta, L., Tomar, N., & Sarin, R. K. (2024) · Emerging Trends in Drugs Addictions and Health · doi:10.1016/j.etdah.2024.100161 · Cited by 5 · see citing works
Lai, Y., Yao, Z., Chang, T., Feng, C., Kuo, T., Luo, Y., Jean, Y., Lin, H. Y., & Wen, Z. (2024) · Environmental Toxicology · doi:10.1002/tox.24447 · Cited by 4 · see citing works
Maji, S., Mohapatra, D., Jena, M., Srinivasan, A., & Maiti, R. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-080500 · Cited by 4 · see citing works
Reply to Hashimoto: Ketamine is not an opioid but requires opioid system for antidepressant actions
Malinow, R., & Klein, M. E. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2002739117 · Cited by 4 · see citing works
Srivastava, J., Yadav, J., & Dubey, N. (2026) · Cognitive Neurodynamics · doi:10.1007/s11571-026-10446-y · Cited by 3 · see citing works
Martins, V., Fazal, L., Oganesian, A., Shah, A. D., Stow, J., Walton, H., & Wilsher, N. E. (2022) · Xenobiotica · doi:10.1080/00498254.2022.2130838 · Cited by 3 · see citing works
The “new wave” of antidepressants: are these agents paradigm-shifters in treating major depression?
Petrescu, B., Marinescu, I., Marinescu, D., Vasiliu, O., Mangalagiu, A., & Cândea, C. (2023) · Psihiatru ro · doi:10.26416/psih.75.4.2023.8926 · Cited by 2 · see citing works
Khamooshi, F., Doraji-Bonjar, S., Modarresi‐Alam, A. R., & Mohammadi, M. H. (2026) · OBM Neurobiology · doi:10.21926/obm.neurobiol.2601318 · Cited by 2 · see citing works
Dhawan, A., Choudhary, S., Gupta, S., Chander, A., & Dhanawat, M. (2023) · Current Drug Therapy · doi:10.2174/1574885519666230913105725 · Cited by 2 · see citing works
NaV1.7 channels are expressed in the lower airways of the human respiratory tract
Hernández‐Plata, E., Alfaro, A., & Becerril, C. (2023) · Respiratory Physiology & Neurobiology · doi:10.1016/j.resp.2023.104034 · Cited by 2 · see citing works
Vitti-Ruela, B. V., Dokkedal‐Silva, V., Piovezan, R. D., Tufik, S., & Andersen, M. L. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.114221 · Cited by 1 · see citing works
Xiao, Y., Hu, X., Xing, W., Yan, J., Wang, R., Li, X., Li, J., Zhang, Z., Sun, J., & Wu, J. M. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1464564 · Cited by 1 · see citing works
Woodard, D. F., Boyle, L., & Zwiebel, S. J. (2025) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002034 · Cited by 1 · see citing works
Ngo, S., Rine, N. I., Kistamgari, S., Smith, G. A., & Hays, H. L. (2025) · Toxicology Communications · doi:10.1080/24734306.2025.2530331 · Cited by 1 · see citing works
Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery
Tanaka, M. (2026) · Biomedicines · doi:10.3390/biomedicines14061265
(2021) · Romanian Journal of Psychiatry & Psychotherapy · doi:10.37897/rjpp.2021.3.3
Hu, X., Xing, W., Wang, R., Li, X., Li, J., Yan, J., Wu, J., & Xiao, Y. (2024) · Research Square · doi:10.21203/rs.3.rs-4119597/v1
Stahl, S. M. (2024) · Prescriber's Guide · doi:10.1017/9781009464772.038
Self-citationTreatment-Resistant Depression: Pharmacological Approach
Díaz, A. P., Quevedo, J., Sanches, M., & Soares, J. C. (2024) · Cambridge University Press eBooks · doi:10.1017/9781108973922.020
Stevenson, K. A., Hamilton, D. V., & Clayton, A. H. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as18
Vázquez, G. H. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33580-8.00022-2
Recent advances in rapid-acting antidepressants
Pan, L., He, Y., Wang, G., & Shen, J. (2025) · Scientia Sinica Chimica · doi:10.1360/ssc-2025-0157
Future Directions of Esketamine Nasal Spray Continuation in Treatment-Resistant Depression
Price, M. Z., & Price, R. L. (2025) · Neuromethods · doi:10.1007/978-1-0716-4599-4_18
Addiction to Dissociative Substances
Louka, C. (2025) · Springer eBooks · doi:10.1007/978-3-031-57159-6_6-1
Resurgence of N-Methyl-d-Aspartate Receptor (NMDAR) Antagonists in Perioperative Medicine
Farag, E. S., Soliman, N., & Seif, J. (2025) · Topics in Pain Management · doi:10.1097/01.tpm.0001169656.75858.7a
Miller, C. O. G. (2025) · Springer eBooks · doi:10.1007/978-3-032-13315-1_2
Lin, H.-Y., Westover, A. N., Lutz, A. S. F., & Jha, M. K. (2026) · Autism Research · doi:10.1002/aur.70287
Dextromethorphan/Bupropion zur Behandlung von Agitation bei Alzheimer-Demenz
Paulzen, M. (2026) · Der Nervenarzt · doi:10.1007/s00115-026-01984-1
Dextromethorphan Beyond the Cough: Exploring Its Psychedelic Potential: A Systematic Review
Hackett, E. P., -, A. C., Hasman, L., Thakur, R., Scott, M. J., & Dworkin, R. H. (2026) · CNS Drugs · doi:10.1007/s40263-026-01305-9
Liu, R., Liu, C., Li, C., Hu, D., Wang, L., Li, Z. J., Feng, D., & Guo, T. (2026) · Medicine · doi:10.1097/md.0000000000049464
Kavuran, İ. B., Önalan, E., Turk, Z. I., & Eröksüz, H. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1910199
The Investment Ecosystem in CNS Drug Development
Mills, B. D., Weninger, S. C., & Bisgaard, P. (2026) · Springer eBooks · doi:10.1007/978-3-032-31497-0_13
- Authors
- Stahl, S. M.
- Affiliations
- University of Cambridge (GB)
- Corresponding author
- Stahl, Stephen M.
- ORCID
- Stahl, Stephen M.
- Venue
- CNS Spectrums
- Publisher
- Cambridge University Press (CUP)
- Published
- 2019-09-30
- Volume
- 24
- Issue
- 5
- Pages
- 461-466
- ISSN
- 1092-8529 (ISSN-L)
- 2165-6509
- OpenAlex
- W2979131874
- Cited by
- 73
- References
- 22
- Citations by year
- 2026: 10 · 2025: 9 · 2024: 18 · 2023: 17 · 2022: 9 · 2021: 7 · 2020: 2 · 2019: 1
- FWCI
- 0.61
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- CNS Spectrums (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- NMDA receptor antagonists, major depressive disorder, treatment-resistant depression, rapid-acting antidepressants, esketamine, monoamine hypothesis
- MeSH terms
- Administration, Oral, Animals, Dextromethorphan, Dopamine, Humans, Norepinephrine, Receptors, N-Methyl-D-Aspartate, Bupropion, Antidepressive Agents, Second-Generation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
